Lian Li

TL;DR: CircSETD3 is a novel tumour suppressor of HCC and is a valuable prognostic biomarker that acts as a sponge for miR-421 and verified that mitogen-activated protein kinase (MAPK)14 is a Novel target of miR -421.

TL;DR: It is indicated that downregulated miR-145 in tumor tissues or peripheral blood predicted unfavorable prognostic outcomes for patients suffering from various malignant tumors and the regulatory mechanisms were observed that numerous tumor-related transcripts could be targeted by miR -145-5p or mi R-145-3p, as well as the expression and function of miR–5p could be regulated by multiple molecules.

TL;DR: Novel predictive models have satisfactory accuracy and discriminatory abilities in predicting the prognosis of HCC patients with MVI after hepatectomy and showed optimal agreement between the predicted and observed survival rates.

TL;DR: SETD3 is associated with tumorigenesis and is a promising biomarker for predicting the prognosis of HCC patients after surgical resection and plays inhibitory role in HCC metastasis partly through DCLK1/PI3K/MMP-2 pathway.

TL;DR: It is demonstrated that the downexpression of microRNA-375 was significantly correlated with poor OS in patients with SCCs and indicated the potential clinical use of miR-375 as a molecular biomarker, particularly in assessing prognosis for patients with ESCC and HNSCC.